Chi-Uk In
Plus aucun poste en cours
Profil
Chi-Uk In was the founder of Neomics Co., Ltd.
which was founded in 2005, where he held the title of Chief Executive Officer & Director.
He also worked as an Independent Director at IMAGENE Co., Ltd.
Mr. In has a graduate degree from the University of Southern California and an undergraduate degree from Seoul National University.
Anciens postes connus de Chi-Uk In
| Sociétés | Poste | Fin |
|---|---|---|
IMAGENE Co., Ltd.
 IMAGENE Co., Ltd. BiotechnologyHealth Technology IMAGENE Co., Ltd. researches and develops treatment for cancer and infectious diseases. Its products include antibody43, chiral building blocks, and aminoacyl-tRNA synthetase inhibitors. The company was founded on December 1, 1997 and is headquartered in Yongin, South Korea. | Directeur/Membre du Conseil | - |
Neomics Co., Ltd.
 Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Fondateur | - |
Formation de Chi-Uk In
| Seoul National University | Undergraduate Degree |
| University of Southern California | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Neomics Co., Ltd.
Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
IMAGENE Co., Ltd.
IMAGENE Co., Ltd. BiotechnologyHealth Technology IMAGENE Co., Ltd. researches and develops treatment for cancer and infectious diseases. Its products include antibody43, chiral building blocks, and aminoacyl-tRNA synthetase inhibitors. The company was founded on December 1, 1997 and is headquartered in Yongin, South Korea. | Health Technology |
